Zacks Investment Research downgraded Mast Therapeutics Inc (NASDAQ:MSTX) to Hold in a statement released earlier today.
- Updated: October 11, 2016
Zacks Investment Research has downgraded Mast Therapeutics Inc (NASDAQ:MSTX) to Hold in a report released on 10/12/2016.
Yesterday Mast Therapeutics Inc (NASDAQ:MSTX) traded -1.04% lower at $0.10. Mast Therapeutics Inc’s 50-day moving average is $0.35 and its two hundred day average is $0.36. With the last close down -73.72% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 3,392,998 shares of Mast Therapeutics Inc exchanged hands, down from an avg. volume of 8,671,740
Recent Performance Chart
With a total market value of $0, Mast Therapeutics Inc has 52 week low of $0.09 and a one year high of $0.71 .
Brief Synopsis About Mast Therapeutics Inc (NASDAQ:MSTX)
Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.